Navigating Refractory RCC: Insights from the TiNivo-2 Trial
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.
Related Articles
Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Efficacy Data
Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen…
Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance
David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.
Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer
E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.
Registration
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Registration Type Early Bird Price (October 7, 2024 –…
Selecting Among Guideline Recommended Treatment Options in Transplant-Eligible NDMM
Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) by considering factors such…
FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.
Bill Could Eliminate Cuts to Medicare Physician Reimbursement
“The cost of caring for a Medicare patient far outpaces the reimbursement that physicians receive for seeing them,” said Congressman Greg Murphy, MD (R-NC).
TYRA-300 Shows Early Promise in Metastatic Urothelial Cancer : Oncology Times
An abstract is unavailable.
Current Protocols Essential Laboratory Techniques
The Essential Laboratory Techniques section of the Current Protocols journal covers good laboratory practices, professional development guides and life science skills.
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC
The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.